Cargando…

SFRP1 reduction results in an increased sensitivity to TGF-β signaling

BACKGROUND: Transforming growth factor (TGF)-β plays a dual role during mammary gland development and tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular migration. The Wnt/β-catenin pathway is also implicated in EMT and inappropriate activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauger, Kelly J, Chenausky, Kerry L, Murray, Molly E, Schneider, Sallie S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041779/
https://www.ncbi.nlm.nih.gov/pubmed/21303533
http://dx.doi.org/10.1186/1471-2407-11-59
_version_ 1782198479690399744
author Gauger, Kelly J
Chenausky, Kerry L
Murray, Molly E
Schneider, Sallie S
author_facet Gauger, Kelly J
Chenausky, Kerry L
Murray, Molly E
Schneider, Sallie S
author_sort Gauger, Kelly J
collection PubMed
description BACKGROUND: Transforming growth factor (TGF)-β plays a dual role during mammary gland development and tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular migration. The Wnt/β-catenin pathway is also implicated in EMT and inappropriate activation of the Wnt/β-catenin signaling pathway leads to the development of several human cancers, including breast cancer. Secreted frizzled-related protein 1 (SFRP1) antagonizes this pathway and loss of SFRP1 expression is frequently observed in breast tumors and breast cancer cell lines. We previously showed that when SFRP1 is knocked down in immortalized non-malignant mammary epithelial cells, the cells (TERT-siSFRP1) acquire characteristics associated with breast tumor initiating cells. The phenotypic and genotypic changes that occur in response to SFRP1 loss are consistent with EMT, including a substantial increase in the expression of ZEB2. Considering that ZEB2 has been shown to interact with mediators of TGF-β signaling, we sought to determine whether TGF-β signaling is altered in TERT-siSFRP1 cells. METHODS: Luciferase reporter assays and real-time PCR analysis were employed to measure TGF-β transcriptional targets. Western blot analysis was used to evaluate TGF-β-mediated ERK1/2 phosphorylation. Migration chamber assays were utilized to quantify cellular migration. TERT-siSFRP1 cells were transfected with Stealth RNAi™ siRNA in order to knock-down the expression of ZEB2. RESULTS: TERT-siSFRP1 cells exhibit a significant increase in both TGF-β-mediated luciferase activity as well as TGF-β transcriptional targets, including Integrin β(3 )and PAI-1. Phosphorylation of ERK1/2 is increased in TERT-siSFRP1 cells in response to enhanced TGF-β signaling. Furthermore, when the TGF-β pathway is blocked with a TGF-βR antagonist (LY364947), cellular migration is significantly hindered. Finally, we found that when ZEB2 is knocked-down, there is a significant reduction in the expression of exogeneous and endogenous TGF-β transcriptional targets and cellular migration is impeded. CONCLUSIONS: We demonstrate that down-regulation of SFRP1 renders mammary epithelial cells more sensitive to TGF-β signaling which can be partially ameliorated by blocking the expression of ZEB2.
format Text
id pubmed-3041779
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30417792011-02-19 SFRP1 reduction results in an increased sensitivity to TGF-β signaling Gauger, Kelly J Chenausky, Kerry L Murray, Molly E Schneider, Sallie S BMC Cancer Research Article BACKGROUND: Transforming growth factor (TGF)-β plays a dual role during mammary gland development and tumorigenesis and has been shown to stimulate epithelial-mesenchymal transition (EMT) as well as cellular migration. The Wnt/β-catenin pathway is also implicated in EMT and inappropriate activation of the Wnt/β-catenin signaling pathway leads to the development of several human cancers, including breast cancer. Secreted frizzled-related protein 1 (SFRP1) antagonizes this pathway and loss of SFRP1 expression is frequently observed in breast tumors and breast cancer cell lines. We previously showed that when SFRP1 is knocked down in immortalized non-malignant mammary epithelial cells, the cells (TERT-siSFRP1) acquire characteristics associated with breast tumor initiating cells. The phenotypic and genotypic changes that occur in response to SFRP1 loss are consistent with EMT, including a substantial increase in the expression of ZEB2. Considering that ZEB2 has been shown to interact with mediators of TGF-β signaling, we sought to determine whether TGF-β signaling is altered in TERT-siSFRP1 cells. METHODS: Luciferase reporter assays and real-time PCR analysis were employed to measure TGF-β transcriptional targets. Western blot analysis was used to evaluate TGF-β-mediated ERK1/2 phosphorylation. Migration chamber assays were utilized to quantify cellular migration. TERT-siSFRP1 cells were transfected with Stealth RNAi™ siRNA in order to knock-down the expression of ZEB2. RESULTS: TERT-siSFRP1 cells exhibit a significant increase in both TGF-β-mediated luciferase activity as well as TGF-β transcriptional targets, including Integrin β(3 )and PAI-1. Phosphorylation of ERK1/2 is increased in TERT-siSFRP1 cells in response to enhanced TGF-β signaling. Furthermore, when the TGF-β pathway is blocked with a TGF-βR antagonist (LY364947), cellular migration is significantly hindered. Finally, we found that when ZEB2 is knocked-down, there is a significant reduction in the expression of exogeneous and endogenous TGF-β transcriptional targets and cellular migration is impeded. CONCLUSIONS: We demonstrate that down-regulation of SFRP1 renders mammary epithelial cells more sensitive to TGF-β signaling which can be partially ameliorated by blocking the expression of ZEB2. BioMed Central 2011-02-08 /pmc/articles/PMC3041779/ /pubmed/21303533 http://dx.doi.org/10.1186/1471-2407-11-59 Text en Copyright ©2011 Gauger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gauger, Kelly J
Chenausky, Kerry L
Murray, Molly E
Schneider, Sallie S
SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title_full SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title_fullStr SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title_full_unstemmed SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title_short SFRP1 reduction results in an increased sensitivity to TGF-β signaling
title_sort sfrp1 reduction results in an increased sensitivity to tgf-β signaling
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041779/
https://www.ncbi.nlm.nih.gov/pubmed/21303533
http://dx.doi.org/10.1186/1471-2407-11-59
work_keys_str_mv AT gaugerkellyj sfrp1reductionresultsinanincreasedsensitivitytotgfbsignaling
AT chenauskykerryl sfrp1reductionresultsinanincreasedsensitivitytotgfbsignaling
AT murraymollye sfrp1reductionresultsinanincreasedsensitivitytotgfbsignaling
AT schneidersallies sfrp1reductionresultsinanincreasedsensitivitytotgfbsignaling